骨髓增生异常综合征 中国就医指南

Myelodysplastic Syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective blood cell production, peripheral cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Pathogenically, MDS arises from acquired somatic mutations in hematopoietic stem or progenitor cells—commonly affecting genes involved in RNA splicing (e.g., SF3B1, SRSF2), DNA methylation (TET2, DNMT3A), chromatin modification (ASXL1), transcription regulation (RUNX1), and signal transduction (RAS pathway). These mutations disrupt normal differentiation and promote apoptosis in the bone marrow, leading to dysplastic morphology across one or more myeloid lineages (erythroid, granulocytic, megakaryocytic). The bone marrow is typically hypercellular, though hypocellular variants exist. Disease progression correlates with accumulating genetic lesions and worsening cytogenetic abnormalities—particularly complex karyotypes or monosomy 7. Epidemiologically, MDS predominantly affects older adults, with a median age at diagnosis of 70–75 years. Incidence rises sharply after age 60, estimated at 3–5 per 100,000 persons annually in Western populations; however, recent epidemiologic studies in China suggest incidence may be underreported but is likely comparable—approximately 2–4 per 100,000 among those aged ≥65. Risk factors include prior exposure to chemotherapy (especially alkylating agents and topoisomerase II inhibitors), radiation therapy, benzene and other organic solvent exposures, smoking, and inherited bone marrow failure syndromes (e.g., Fanconi anemia, telomere biology disorders). Age remains the strongest non-modifiable risk factor. Quality of life in MDS is significantly impaired—not only due to fatigue, shortness of breath, recurrent infections, and bleeding tendencies stemming from anemia, neutropenia, and thrombocytopenia—but also from psychological burden, treatment-related side effects (e.g., transfusion iron overload, immunosuppression), and uncertainty around disease evolution. Patients frequently report reduced physical functioning, social withdrawal, anxiety about AML transformation, and diminished capacity for daily activities and employment. Supportive care—including red blood cell and platelet transfusions, growth factor use (e.g., erythropoietin analogs), and iron chelation—is foundational, yet does not alter disease biology. Higher-risk MDS requires disease-modifying therapies such as hypomethylating agents (azacitidine, decitabine), lenalidomide (particularly in del(5q) cases), or allogeneic hematopoietic stem cell transplantation—the only potentially curative option, albeit limited by age, comorbidities, and donor availability. Comprehensive management demands multidisciplinary coordination between hematologists, transfusion medicine specialists, psychologists, and palliative care teams to optimize both survival and patient-centered outcomes.

# 骨髓增生异常综合征（MDS）治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

• •低危患者（IPSS-R ≤3.0，无严重血细胞减少）：观察随访+支持治疗（输血、去铁治疗、EPO/G-CSF），年均费用 8,000–35,000元（含每月血常规、铁蛋白、骨髓涂片复查及年度染色体/FISH检测）。
• •中高危药物治疗：地西他滨（5天方案，每28天1周期），6周期为1疗程；费用 42,000–68,000元/疗程（含药费、住院护理、血象监测、肝肾功能及感染筛查）。

二、根治性治疗方案

• •异基因造血干细胞移植（allo-HSCT）：适用于≤65岁、ECOG≤2分、有HLA相合供者者。术前检查（全项感染筛查、心肺功能、供者配型等） 12,000–18,000元；全流程费用（预处理、移植、+100天抗排异及感染防治） 350,000–520,000元（医保报销后自付约12–25万元）。

三、特殊复杂情况

• •TP53突变/复杂核型/继发AML转化：维奈托克联合阿扎胞苷，年治疗费 480,000–620,000元；难治复发者桥接临床试验（部分免费，筛选及基线检查 5,000–10,000元）。

四、方案快速选择指南

• •预算有限/老年低危者 → 支持治疗（年均≤3万元）；
• •中高危可耐受者 → 地西他滨（首年投入≤7万元）；
• •年轻高危/有供者者 → 移植（优先医保定点中心，争取大病专项补助）。